Mentoring in pediatric oncology: a report from the Children’s Oncology Group Young Investigator Committee

2023-08-23T16:22:05-04:00August 21st, 2013|

Levy AS1, Pyke-Grimm KA, Lee DA, Palla SL, Naranjo A, Saulnier Sholler G, Gratias E, Maloney K, Parshankar F, Lee-Scott M, Beierle EA, Gow K, Kim GE, Hunger S, Smith FO, Horton TM J Mentoring in pediatric oncology: a report from the Children's Oncology Group Young Investigator Committee. Pediatr Hematol Oncol. 2013 Aug;35(6):456-61.

Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors

2023-08-23T16:21:12-04:00August 17th, 2013|

Morgenstern DA, Marzouki M, Bartels U, Irwin MS, Sholler GL, Gammon J, Yankanah R, Wu B, Samson Y, Baruchel S. Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors.  Pediatr Blood Cancer. 2013 Aug 17. doi: 10.1002/pbc.24656. [Epub ahead of print]

Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma

2023-08-23T16:09:41-04:00May 12th, 2013|

Eslin D, Sankpal U, Lee C, Sutphin R, Maliakal P, Currier E, Saulnier Sholler G, Khan M, and Basha R.. Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma. Mol Carcinog. 2013 May;52(5):377-86

A Pilot Trial Testing the Feasibility of Using Molecular-Guided Therapy in Patients with Recurrent Neuroblastoma. Journal of Cancer Therapy

2023-08-23T14:27:57-04:00June 12th, 2012|

Saulnier Sholler G, Ferguson W, Bergendahl G, Currier E, Lenox SR, Bond J, Slavik M, Roberts W,  Mitchell D, Eslin D, Kraveka J, Kaplan J, Parikh N, Malempati S, Hanna  G, Eugster E, Cherba D,  Miller J, Webb C. A Pilot Trial Testing the Feasibility of Using Molecular-Guided Therapy in Patients with Recurrent Neuroblastoma. Journal of [...]

Neuroblastoma: Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention

2023-08-23T10:46:38-04:00March 12th, 2012|

Bachmann AS, Geerts D, Saulnier Sholler G: Neuroblastoma: Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention, In: Pediatric Cancer, Volume 1, Neuroblastoma: Diagnosis, Therapy, and Prognosis, Ed. Hayat MA, Springer, Heidelberg, Germany, 2012

AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport

2023-08-23T10:40:21-04:00March 2nd, 2012|

Samal K, Zhao P, Kendzicky A, Yco LP, McClung H, Gerner E, Burns M, Bachmann AS, Saulnier Sholler G. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.  Int J Cancer. 2013 Mar 2. doi: 10.1002/ijc.28139. [Epub ahead of print]

Oral RKS262 Reduces Tumor Burden in a Neuroblastoma (NB) Xenograft Animal Model and Mediates Cytotoxicity through SAPK/JNK and ROS Activation in Vitro

2023-08-23T10:36:32-04:00February 12th, 2011|

Singh R, Dorf L, DeMartino A, Illenye S, Koto K, Ashikaga T, Kwang Kim K, Brard L, Saulnier Sholler G. Oral RKS262 Reduces Tumor Burden in a Neuroblastoma (NB) Xenograft Animal Model and Mediates Cytotoxicity through SAPK/JNK and ROS Activation in Vitro. Cancer Biol Ther. 2011, 11:12, 1-10.

Go to Top